当前位置： SCI文献检索 > CLINICAL PHARMACOKINETICS期刊下所有文献 > Dose-Dependent Bioavailability and CYP3A Inhibition Contribute to Non-Linear Pharmacokinetics of Voriconazole.

Dose-Dependent Bioavailability and CYP3A Inhibition Contribute to Non-Linear Pharmacokinetics of Voriconazole.

Abstract：

:Voriconazole is both a substrate and a potent inhibitor of cytochrome P450 (CYP) 3A. It has a high bioavailability and non-linear pharmacokinetics. We investigated the pharmacokinetics and metabolism of 50 mg and 400 mg doses of intravenous and oral voriconazole in 14 healthy volunteers. Concurrently, we determined systemic and presystemic CYP3A activity with microdosed midazolam. Bioavailability of voriconazole 50 mg was 39 % compared with 86 % of the 400 mg dose. Voriconazole area under the concentration-time curve extrapolated to infinity (AUC∞) was 416 and 16,700 h·ng/mL for the 50 and 400 mg oral doses, respectively, and 1110 and 19,760 h·ng/mL for the 50 and 400 mg intravenous doses, respectively. Midazolam metabolism was dose-dependently inhibited by voriconazole. Dose-dependent autoinhibition of CYP3A-dependent first-pass metabolism and systemic metabolism is a possible explanation for the dose-dependent bioavailability and elimination of voriconazole, either as additional mechanism to, or instead of, saturation of presystemic metabolism. Higher bioavailability and non-linear pharmacokinetics are expected to be a common property of drugs that are substrates and inhibitors of CYP3A, e.g. clarithromycin.

journal_name

Clin Pharmacokinet

journal_title

Clinical pharmacokinetics

authors

Hohmann N,Kocheise F,Carls A,Burhenne J,Weiss J,Haefeli WE,Mikus G

doi

10.1007/s40262-016-0416-1

subject

Has Abstract

pub_date

2016-12-01 00:00:00

pages

1535-1545

issue

12

eissn

0312-5963

issn

1179-1926

pii

10.1007/s40262-016-0416-1

journal_volume

55

pub_type

临床试验,杂志文章

相关文献

CLINICAL PHARMACOKINETICS文献大全
  • Drug protein binding and the nephrotic syndrome.

    abstract：:A reduction in plasma albumin concentration, as seen in patients with the nephrotic syndrome, is usually associated with a decrease in plasma protein binding of highly bound drugs. Therefore, the fraction of the unbound drug increases, but the absolute free concentration remains essentially unchanged due to a compensa...

    journal_title：Clinical pharmacokinetics

    pub_type： 杂志文章,评审

    doi：10.2165/00003088-197601010-00003

    authors： Gugler R,Azarnoff DL

    更新日期：1976-01-01 00:00:00

  • A Phase I Pharmacokinetic Study of Trastuzumab Emtansine (T-DM1) in Patients with Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function.

    abstract：OBJECTIVE:The aim of this study was to evaluate the pharmacokinetics (PK) of trastuzumab emtansine (T-DM1) and relevant analytes in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer and hepatic impairment. METHODS:Patients were enrolled in three independent parallel cohort...

    journal_title：Clinical pharmacokinetics

    pub_type： 杂志文章,多中心研究

    doi：10.1007/s40262-016-0496-y

    authors： Li C,Agarwal P,Gibiansky E,Jin JY,Dent S,Gonçalves A,Nijem I,Strasak A,Harle-Yge ML,Chernyukhin N,LoRusso P,Girish S

    更新日期：2017-09-01 00:00:00

  • New insulin analogues and routes of delivery: pharmacodynamic and clinical considerations.

    abstract：:Analogues of human insulin have been developed to more closely replicate the physiology of meal-related and basal insulin secretion. Three rapid-acting analogues and two basal analogues are available for clinical use. Insulin aspart and insulin lispro have nearly identical pharmacokinetic and pharmacodynamic profiles ...

    journal_title：Clinical pharmacokinetics

    pub_type： 杂志文章,评审

    doi：10.2165/00003088-200847090-00003

    authors： Roach P

    更新日期：2008-01-01 00:00:00

  • Semi-Mechanistic Model for Predicting the Dosing Rate in Children and Neonates for Drugs Mainly Eliminated by Cytochrome Metabolism.

    abstract：BACKGROUND AND OBJECTIVE:A simple approach is proposed to predict drug clearance in children when no paediatric data are available for drugs metabolised by cytochromes. METHODS:The maturation functions of cytochrome activity and binding proteins in plasma were combined with several measures of body size to describe dr...

    journal_title：Clinical pharmacokinetics

    pub_type： 杂志文章

    doi：10.1007/s40262-017-0596-3

    authors： Cerruti L,Bleyzac N,Tod M

    更新日期：2018-07-01 00:00:00

  • Renal insufficiency has no effect on the pharmacokinetics of vicriviroc in a ritonavir-containing regimen.

    abstract：BACKGROUND AND OBJECTIVE:Vicriviroc is a small-molecule CCR5 antagonist currently in development for the treatment of HIV in patients on a regimen containing a ritonavir-boosted protease inhibitor. As renal disease and renal dysfunction are prevalent in the HIV-infected population, patients with varying degrees of rena...

    journal_title：Clinical pharmacokinetics

    pub_type： 杂志文章,随机对照试验

    doi：10.2165/11319470-000000000-00000

    authors： Kasserra C,Sansone-Parsons A,Keung A,Tetteh E,Assaf M,O'Mara E,Marbury T

    更新日期：2010-06-01 00:00:00

  • Development of a Whole-Body Physiologically Based Pharmacokinetic Approach to Assess the Pharmacokinetics of Drugs in Elderly Individuals.

    abstract：BACKGROUND:Because of the vulnerability and frailty of elderly adults, clinical drug development has traditionally been biased towards young and middle-aged adults. Recent efforts have begun to incorporate data from paediatric investigations. Nevertheless, the elderly often remain underrepresented in clinical trials, e...

    journal_title：Clinical pharmacokinetics

    pub_type： 杂志文章

    doi：10.1007/s40262-016-0422-3

    authors： Schlender JF,Meyer M,Thelen K,Krauss M,Willmann S,Eissing T,Jaehde U

    更新日期：2016-12-01 00:00:00

  • Exposure-effect population model of inolimomab, a monoclonal antibody administered in first-line treatment for acute graft-versus-host disease.

    abstract：BACKGROUND AND OBJECTIVE:Inolimomab, a monoclonal antibody against interleukin (IL)-2Ralpha (CD25) has shown promising results in the treatment of corticosteroid-resistant acute graft-versus-host disease (GvHD). The objective of the present study was to characterise the pharmacokinetic and pharmacodynamic properties of...

    journal_title：Clinical pharmacokinetics

    pub_type： 杂志文章

    doi：10.2165/00003088-200746050-00004

    authors： Dartois C,Freyer G,Michallet M,Hénin E,You B,Darlavoix I,Vermot-Desroches C,Tranchand B,Girard P

    更新日期：2007-01-01 00:00:00

  • Comparative serum prednisone and prednisolone concentrations following administration to patients with chronic active liver disease.

    abstract：:Following administration of equivalent oral doses (30mg) of either prednisone or prednisolone to 5 patients with chronic active liver disease who had failed to respond to therapy, 5 patients with chronic active liver disease in remission induced by prednisone, and 7 healthy volunteers, corticosteroid concentrations we...

    journal_title：Clinical pharmacokinetics

    pub_type： 杂志文章

    doi：10.2165/00003088-198207050-00005

    authors： Uribe M,Summerskill WH,Go VL

    更新日期：1982-09-01 00:00:00

  • Disposition of antipyrine and phenytoin correlated with age and liver volume in man.

    abstract：:The half-life and metabolic clearance rate (MCR) of antipyrine and phenytoin were determined in 14 young (mean age: 28.8 +/- 8.3 (SD) years] and in 14 elderly [mean age: 83.5 +/- 7.1 (SD) years] subjects and correlated with liver volume, which was determined by ultrasonic scanning, to see if an age-dependent differenc...

    journal_title：Clinical pharmacokinetics

    pub_type： 杂志文章

    doi：10.2165/00003088-198106050-00005

    authors： Bach B,Hansen JM,Kampmann JP,Rasmussen SN,Skovsted L

    更新日期：1981-09-01 00:00:00

  • Clinical pharmacokinetics of mifepristone.

    abstract：:Mifepristone is a steroidal antiprogestin and antiglucocorticoid acting at the receptor level. The aromatic dimethylaminophenyl side chain in position 11 of the steroid structure is essential for the antagonistic properties of mifepristone. The pharmacokinetics of mifepristone are characterised by rapid absorption, a ...

    journal_title：Clinical pharmacokinetics

    pub_type： 杂志文章

    doi：10.2165/00003088-199733010-00002

    authors： Heikinheimo O

    更新日期：1997-07-01 00:00:00

  • Clinical pharmacokinetics of dothiepin. Single-dose kinetics in patients and prediction of steady-state concentrations.

    abstract：:The pharmacokinetics of dothiepin were evaluated in 9 depressed patients following a single oral dose of 75 mg. Blood and plasma concentrations of dothiepin and 2 major metabolites, northiaden and dothiepin S-oxide, were measured by gas chromatography/mass fragmentography. The mean (+/-SD) peak plasma concentrations o...

    journal_title：Clinical pharmacokinetics

    pub_type： 杂志文章

    doi：10.2165/00003088-198308020-00004

    authors： Maguire KP,Norman TR,McIntyre I,Burrows GD

    更新日期：1983-03-01 00:00:00

  • A mechanistic approach for the scaling of clearance in children.

    abstract：BACKGROUND AND OBJECTIVE:Clearance is an important pharmacokinetic concept for scaling dosage, understanding the risks of drug-drug interactions and environmental risk assessment in children. Accurate clearance scaling to children requires prior knowledge of adult clearance mechanisms and the age-dependence of physiolo...

    journal_title：Clinical pharmacokinetics

    pub_type： 杂志文章

    doi：10.2165/00003088-200645070-00004

    authors： Edginton AN,Schmitt W,Voith B,Willmann S

    更新日期：2006-01-01 00:00:00

  • Population pharmacokinetic analysis of tesamorelin in HIV-infected patients and healthy subjects.

    abstract：BACKGROUND AND OBJECTIVES:Tesamorelin is a synthetic analogue of growth hormone-releasing factor (GRF), which increases basal and pulsatile growth hormone (GH) secretion and subsequently increases insulin-like growth factor (IGF)-1. Limited information is available about the pharmacokinetics of this compound. Consequen...

    journal_title：Clinical pharmacokinetics

    pub_type： 杂志文章,随机对照试验

    doi：10.1007/s40262-014-0202-x

    authors： González-Sales M,Barrière O,Tremblay PO,Nekka F,Mamputu JC,Boudreault S,Tanguay M

    更新日期：2015-03-01 00:00:00

  • Patient-controlled analgesic therapy. Part I: Pharmacokinetics of pethidine in the per- and postoperative periods.

    abstract：:The influence of anaesthesia and surgery on the pharmacokinetics of pethidine (meperidine) was studied in 12 patients. Plasma pethidine concentrations in central venous blood collected during anaesthesia and the ensuing postoperative hours were by gas chromatography with electron capture detection. Postoperative analg...

    journal_title：Clinical pharmacokinetics

    pub_type： 杂志文章

    doi：10.2165/00003088-198207020-00004

    authors： Tamsen A,Hartvig P,Fagerlund C,Dahlström B

    更新日期：1982-03-01 00:00:00

  • Population-Pharmacokinetic Modeling of Tildrakizumab (MK-3222), an Anti-Interleukin-23-p19 Monoclonal Antibody, in Healthy Volunteers and Subjects with Psoriasis.

    abstract：BACKGROUND:Tildrakizumab is an anti-interleukin-23p19 monoclonal antibody recently approved for the treatment of chronic plaque psoriasis. METHODS:This analysis characterizes the population pharmacokinetics of subcutaneous tildrakizumab and identifies covariates influencing exposure in 2098 healthy volunteers and subj...

    journal_title：Clinical pharmacokinetics

    pub_type： 杂志文章,随机对照试验

    doi：10.1007/s40262-019-00743-7

    authors： Jauslin P,Kulkarni P,Li H,Vatakuti S,Hussain A,Wenning L,Kerbusch T

    更新日期：2019-08-01 00:00:00

  • Clinical pharmacokinetics of doxycycline and minocycline.

    abstract：:Doxycycline and minocycline are second-generation tetracyclines. They are readily absorbed, distributed throughout the organism as a function of their lipophilicity and eliminated in both the urine and the faeces. The influence of age, renal disease, malnutrition and hyperlipidaemia is reviewed, together with the main...

    journal_title：Clinical pharmacokinetics

    pub_type： 杂志文章,评审

    doi：10.2165/00003088-198815060-00001

    authors： Saivin S,Houin G

    更新日期：1988-12-01 00:00:00

  • Lopinavir/ritonavir pharmacokinetics in HIV and hepatitis C virus co-infected patients without liver function impairment: influence of liver fibrosis.

    abstract：BACKGROUND AND OBJECTIVE:To assess the influence of hepatitis C virus (HCV) co-infection and the extent of liver fibrosis on lopinavir/ritonavir pharmacokinetics in HIV-infected patients without liver function impairment. METHODS:Cross-sectional, comparative study enrolling HIV-infected adults receiving lopinavir/rito...

    journal_title：Clinical pharmacokinetics

    pub_type： 杂志文章

    doi：10.2165/00003088-200746010-00005

    authors： Moltó J,Valle M,Blanco A,Negredo E,DelaVarga M,Miranda C,Miranda J,Domingo P,Vilaró J,Tural C,Costa J,Barbanoj MJ,Clotet B

    更新日期：2007-01-01 00:00:00

  • Population pharmacokinetics and dosing recommendations for cisplatin during intraperitoneal peroperative administration: development of a limited sampling strategy for toxicity risk assessment.

    abstract：BACKGROUND:Ovarian cancer is the leading cause of gynaecological cancer-related death in Western countries. Intraperitoneal (IP) peroperative chemotherapy is an interesting therapeutic option. However, very few data are available regarding pharmacokinetics and especially population pharmacokinetics. PATIENTS AND METHO...

    journal_title：Clinical pharmacokinetics

    pub_type： 杂志文章

    doi：10.2165/00003088-200948030-00003

    authors： Royer B,Jullien V,Guardiola E,Heyd B,Chauffert B,Kantelip JP,Pivot X

    更新日期：2009-01-01 00:00:00

  • Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 Inhibitor.

    abstract：:Proprotein convertase subtilisin/kexin type 9 (PCSK9) increases plasma low-density lipoprotein cholesterol (LDL-C) by decreasing expression of the LDL receptor on hepatic cells. Evolocumab is a human monoclonal immunoglobulin G2 that binds specifically to human PCSK9 to reduce LDL-C. Evolocumab exhibits nonlinear kine...

    journal_title：Clinical pharmacokinetics

    pub_type： 杂志文章,评审

    doi：10.1007/s40262-017-0620-7

    authors： Kasichayanula S,Grover A,Emery MG,Gibbs MA,Somaratne R,Wasserman SM,Gibbs JP

    更新日期：2018-07-01 00:00:00

  • Clinical pharmacokinetic and pharmacodynamic considerations in patients with liver disease. An update.

    abstract：:The effects of liver disease on pharmacokinetics and pharmacodynamics are highly variable, and difficult to predict as the mechanisms of these effects are not well understood. Since the majority of the published literature is concerned with cirrhotic liver disease, this review also focuses mainly on this area. Four di...

    journal_title：Clinical pharmacokinetics

    pub_type： 杂志文章,评审

    doi：10.2165/00003088-199529050-00005

    authors： Morgan DJ,McLean AJ

    更新日期：1995-11-01 00:00:00

  • Dose Reduction of Caspofungin in Intensive Care Unit Patients with Child Pugh B Will Result in Suboptimal Exposure.

    abstract：BACKGROUND AND OBJECTIVES:Caspofungin is an echinocandin antifungal agent used as first-line therapy for the treatment of invasive candidiasis. The maintenance dose is adapted to body weight (BW) or liver function (Child-Pugh score B or C). We aimed to study the pharmacokinetics of caspofungin and assess pharmacokineti...

    journal_title：Clinical pharmacokinetics

    pub_type： 杂志文章

    doi：10.1007/s40262-015-0347-2

    authors： Martial LC,Brüggemann RJ,Schouten JA,van Leeuwen HJ,van Zanten AR,de Lange DW,Muilwijk EW,Verweij PE,Burger DM,Aarnoutse RE,Pickkers P,Dorlo TP

    更新日期：2016-06-01 00:00:00

  • Pharmacokinetics of pancuronium in patients undergoing coronary artery surgery with and without low dose dopamine.

    abstract：:Pancuronium is frequently used in coronary artery surgery, but its pharmacokinetics in these patients are still unknown. It is possible that dopamine, administered to prevent renal impairment induced by the surgery, might promote the elimination of pancuronium. Therefore, the pharmacokinetics of a bolus dose of pancur...

    journal_title：Clinical pharmacokinetics

    pub_type： 杂志文章

    doi：10.2165/00003088-199019060-00005

    authors： Wierda JM,van der Starre PJ,Scaf AH,Kloppenburg WD,Proost JH,Agoston S

    更新日期：1990-12-01 00:00:00

  • Pharmacokinetics of antibiotics in pregnancy and labour.

    abstract：:Few of the articles published on antibiotics and pregnancy are concerned with pharmacokinetics. It is particularly difficult to evaluate possible alterations in pharmacokinetic parameters that may be due to pregnancy. Most data available have been obtained in connection with abortion or delivery. Such data may not be ...

    journal_title：Clinical pharmacokinetics

    pub_type： 杂志文章,评审

    doi：10.2165/00003088-197904040-00003

    authors： Philipson A

    更新日期：1979-07-01 00:00:00

  • Clinical pharmacology of 5-fluorouracil.

    abstract：:5-Fluorouracil, first introduced as a rationally synthesized anticancer agent 30 years ago, continues to be widely used in the management of several common malignancies including cancer of the colon, breast and skin. This drug, an analogue of the naturally occurring pyrimidine uracil, is metabolised via the same metab...

    journal_title：Clinical pharmacokinetics

    pub_type： 杂志文章,评审

    doi：10.2165/00003088-198916040-00002

    authors： Diasio RB,Harris BE

    更新日期：1989-04-01 00:00:00

  • Comparative study of gentamicin release from normal and low viscosity acrylic bone cement.

    abstract：:The pharmacokinetics of gentamicin were studied after total hip joint arthroplasties in 2 groups of 10 patients. The prosthesis was performed in the first group with 'Palacos R plus gentamicin' (normal viscosity), manufactured by Schering, and in the second group with 'Cerafix genta R' (low viscosity) manufactured by ...

    journal_title：Clinical pharmacokinetics

    pub_type： 杂志文章

    doi：10.2165/00003088-199019040-00005

    authors： Bunetel L,Segui A,Cormier M,Langlais F

    更新日期：1990-10-01 00:00:00

  • Clinical pharmacokinetics and pharmacodynamics of buspirone, an anxiolytic drug.

    abstract：:Buspirone is an anxiolytic drug given at a dosage of 15 mg/day. The mechanism of action of the drug is not well characterised, but it may exert its effect by acting on the dopaminergic system in the central nervous system or by binding to serotonin (5-hydroxytryptamine) receptors. Following a oral dose of buspirone 20...

    journal_title：Clinical pharmacokinetics

    pub_type： 杂志文章,评审

    doi：10.2165/00003088-199936040-00003

    authors： Mahmood I,Sahajwalla C

    更新日期：1999-04-01 00:00:00

  • Effect of hepatic and renal impairment on the pharmacokinetics of dalcetrapib: altered distribution of the active thiol?

    abstract：BACKGROUND AND OBJECTIVE:Dalcetrapib, a cholesteryl ester transfer protein (CETP) modulator, is a thioester pro-drug that is rapidly hydrolysed to generate a pharmacologically active thiol. The thiol covalently binds to plasma proteins as mixed disulfides, extensively distributes into plasma lipoprotein fractions, and ...

    journal_title：Clinical pharmacokinetics

    pub_type： 临床试验,杂志文章

    doi：10.1007/s40262-013-0035-z

    authors： Phelan M,Anzures-Cabrera J,Carlile DJ,Rowell L,Kuhlmann O,Arold G,Robson R,Bentley D

    更新日期：2013-04-01 00:00:00

  • Clinical pharmacokinetics of dorzolamide.

    abstract：:Dorzolamide is a carbonic anhydrase inhibitor for topical ophthalmic application. It is used in the treatment of glaucoma to lower the intraocular pressure. After absorption via the cornea and stroma, it inhibits carbonic anhydrase in the ciliary process, which leads to a reduction of aqueous humour production and the...

    journal_title：Clinical pharmacokinetics

    pub_type： 杂志文章,评审

    doi：10.2165/00003088-200241030-00004

    authors： Martens-Lobenhoffer J,Banditt P

    更新日期：2002-01-01 00:00:00

  • Prediction of Free from Total Mycophenolic Acid Concentrations in Stable Renal Transplant Patients: A Population-Based Approach.

    abstract：BACKGROUND:A population pharmacokinetic (PK) protein-binding model was developed to (1) predict free mycophenolic acid (fMPA) based on total MPA (tMPA) concentrations in renal transplant patients, to establish the therapeutic range of fMPA through pharmacokinetic-pharmacodynamic studies; and (2) provide a guideline for...

    journal_title：Clinical pharmacokinetics

    pub_type： 杂志文章

    doi：10.1007/s40262-017-0603-8

    authors： Colom H,Andreu F,van Gelder T,Hesselink DA,de Winter BCM,Bestard O,Torras J,Cruzado JM,Grinyó JM,Lloberas N

    更新日期：2018-07-01 00:00:00

  • Higher Febuxostat Exposure Observed in Asian Compared with Caucasian Subjects Independent of Bodyweight.

    abstract：BACKGROUND AND OBJECTIVE:Febuxostat is a xanthine oxidase inhibitor indicated for gout and hyperuricemia. This work investigates potential clinically relevant covariates for febuxostat pharmacokinetics with a special focus on Asian race and bodyweight. METHODS:Febuxostat plasma concentrations from 141 male subjects we...

    journal_title：Clinical pharmacokinetics

    pub_type： 杂志文章

    doi：10.1007/s40262-020-00943-6

    authors： Rekić D,Johansson S,Leander J

    更新日期：2020-09-19 00:00:00